Miami Beach, FLNCT04830137Now EnrollingIRB Ready

Chronic Lymphocytic Leukemia (CLL) Clinical Trial in Miami Beach, FL

Access cutting-edge chronic lymphocytic leukemia (cll) treatment through this clinical trial at a research site in Miami Beach. Study-provided care at no cost to qualified participants.

Sponsored by Nurix Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Miami Beach location

Preparing your pre-screening questions…

Expert Care in Miami Beach

Access chronic lymphocytic leukemia (cll) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic lymphocytic leukemia (cll) treatment provided free

Apply for This Miami Beach Location

Check if you qualify for this chronic lymphocytic leukemia (cll) clinical trial in Miami Beach, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Miami Beach

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Miami Beach site if eligible
  4. 4Begin participation

About This Chronic Lymphocytic Leukemia (CLL) Study in Miami Beach

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

Sponsor: Nurix Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Patients must be ≥ 18 years of age
Patients must have measurable disease per disease-specific response criteria
Patients with indolent forms of NHL must meet the criteria requiring systemic treatment (i.e., iwCLL, IWG, Lugano Classification of Lymphoma response criteria, or International PCNSL Collaborative Group response criteria)
Patients with transformed lymphoma are eligible for the study with the exception of those detailed in

Exclusion Criteria

#1: Prolymphocytic leukemia, MCL with blastoid histology, MCL with pleomorphic morphology, or MCL with known TP53 mutation
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (non-PCNSL indications) or 0 - 2 (PCNSL patients)
Adequate organ and bone marrow function
Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol Inclusion Criteria for Patients in Phase 1a:
Have histologically confirmed R/R CLL, SLL, WM, MCL, and MZL, FL, DLBCL, or PCNSL
Received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM or PCNSL) and have no other therapies known to provide clinical benefit
Must require systemic therapy Inclusion Criteria for Patients in Phase 1b:
Must have one of the following histologically documented R/R B-cell malignancies:
CLL/SLL whose disease has failed treatment with a BTKi;
MCL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen
FL or MZL whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTKi
PCNSL whose disease failed at least 1 prior line of treatment
DLBCL whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen, or another/ palliative regimen (either progressed post stem cell transplant or transplant-ineligible) Exclusion Criteria:
Active, uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia
History of known/suspected other autoimmune disease (exception(s): patients with alopecia, vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed.)
Unable to swallow capsules or have a condition that may interfere in the delivery, absorption, or metabolism of the study drug
Bleeding diathesis, or other known risk for acute blood loss
Patients requiring ongoing treatment with warfarin or an equivalent vitamin K antagonist and within 7 days prior to the first dose of study drug
Prior radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation)
Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for alopecia, hypothyroidism with adequate replacement therapy, hypopituitarism with adequate replacement therapy, peripheral neuropathy or hematologic parameters meeting inclusion criteria).
Active known second malignancy. Exception: patients with non-metastatic, non-melanoma skin cancer are eligible
Patient has had major surgery (e.g. requiring general anesthesia) within 4 weeks before the planned first dose of study drug
Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: patients with well-controlled HIV (e.g., CD4 \> 350/mm3 and undetectable viral load) are eligible.
Current active liver disease from any cause
Active viral reactivation (e.g., CMV or EBV)
Use of systemic corticosteroids exceeding 20 mg/day prednisone (or equivalent) for non-PCNSL indications within 15 days prior to the planned start of study drug. PCNSL patients may not exceed corticosteroid doses of 40 mg/day prednisone (or equivalent) and should be on a stable or decreasing dose for 7 days prior to planned study start.
Use of non-steroidal immunosuppressive drugs within 30 days prior to start of the study
Clinically significant, uncontrolled cardiac, cardiovascular disease, or history of myocardial infarction within 6 months of planned start of study drug
Administration of any strong cytochrome P450 3A (CYP3A) inducers or inhibitors for 14 days prior to the first dose of study drug, and any P-glycoprotein inhibitors (for 2 days) or moderate inducers of CYP3A for 7 days

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Miami Beach?

Yes, this clinical trial (NCT04830137) has an active research site in Miami Beach, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Lymphocytic Leukemia (CLL) Treatment Options in Miami Beach, FL

If you're searching for chronic lymphocytic leukemia (cll) treatment options in Miami Beach, FL, this clinical trial (NCT04830137) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Miami Beach research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic lymphocytic leukemia (cll) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic lymphocytic leukemia (cll) clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Miami Beach, FL

See all leukemia clinical trials recruiting in Miami Beach — not just this study.

Browse Leukemia Trials in Miami Beach →

Browse More Trials by Condition

Leukemia TrialsChronic Lymphocytic Leukemia TrialsHeart Attack TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Miami Beach?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Miami Beach, FL